Lilly to Acquire Merida Biosciences in Up to $2.88B Autoimmune Deal
- Eli Lilly will acquire privately held Merida Biosciences for up to $2.88 billion, combining upfront and milestone payments; the deal is expected to close in Q4 2026.
- Merida engineers biologics that selectively degrade disease-causing autoantibodies, aiming to target the root biology of autoimmune and allergic disease rather than broadly suppress immunity.
- Lead candidate MER511 is in early-stage testing for Graves' disease and thyroid eye disease, with initial data pointing to reductions in thyroid-stimulating autoantibodies.
- The pipeline also includes MER769, a preclinical antibody targeting underlying allergy biology, with potential relevance to food allergy, asthma, and chronic urticaria.
- The deal is Lilly's 13th acquisition of 2026, extending an obesity/diabetes-funded buying spree into new autoimmune and allergy modalities.
Autoantibody degradation goes after a gap FcRn inhibitors like Vyvgart can't close — those broadly dial down IgG, this targets the specific rogue antibodies. If MER511's Graves' data hold, it's a cleaner mechanism story than another B-cell depleter. The structure says Lilly isn't paying for hope: milestone-heavy pricing on preclinical/Phase 1 assets pushes the risk onto Merida's team hitting data, not onto Lilly's balance sheet. $2.88B is reasonable for a validated new modality, rich if MER511 stalls. It slots next to lebrikizumab and mirikizumab without cannibalizing either. The real signal is deal #13 this year — Lilly's recycling GLP-1 cash into next-gen immunology and allergy bets while it still has the war chest to shop early.
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies ↗